Importantly, the increase in autophagy flux leads to reduction (or enhanced clearance) of intracellular or intraneuronal protein levels, including Aβ and tau, in animal models [18, 19, 62–64], suggesting that the observed reduction on Aβ PET and CSF and plasma Aβ and tau in AD patients may be due to the effect of nilotinib on neuronal autophagy (Fig. 6). This evidence concerns the gene MAPT and Alzheimer disease.